NCT03339778View on ClinicalTrials.gov

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

September 30, 2017

Conditions
Primary Immunodeficiency
Sponsors
All Listed Sponsors
lead

IMMUNOe Research Centers

INDUSTRY

NCT03339778 - The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations | Biotech Hunter | Biotech Hunter